NCT00025207View on ClinicalTrials.gov

Gefitinib in Treating Patients With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

February 28, 2006

Conditions
Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
Interventions
DRUG

gefitinib

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00025207 - Gefitinib in Treating Patients With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter